值得一提的是，10月21日，思派健康发布公告，公司获受托人告知，于本公告日期，受托人已于市场上购买合共2928万股股份，总代价为约1.95亿港元，占公司于本公告日期已发行股份总数约3.84%。据此购买的股份将用作该计划项下合资格参与者的奖励，以鼓励彼等为集团作出贡献。于本公告日期，公司尚未根据该计划授出任何股份。Sipai Health (00314) rose over 5%, as of the time of writing, up 5.08%, priced at 6 Hong Kong dollars, with a transaction volume of 11.0275 million Hong Kong dollars.
According to Zhitong Finance APP, Sipai Health (00314) rose over 5%, as of the time of writing, up 5.08%, priced at 6 Hong Kong dollars, with a transaction volume of 11.0275 million Hong Kong dollars.
In recent news, Sipai Health signed a strategic cooperation agreement with Jianyi Technology in Shanghai. The company stated that the strategic cooperation with Jianyi Technology is an important consensus reached based on common development concepts and strategic objectives. In the future, they will fully utilize and combine their respective layout advantages, business advantages, technological resources, and customer resources to conduct extensive and in-depth cooperation around building a "health insurance + medical health management" model and achieving value-based medical care.
It is worth mentioning that on October 21, Sipai Health released a statement indicating that the trustee informed them that as of the date of this announcement, the trustee had purchased a total of 29.28 million shares on the market at a total cost of approximately 0.195 billion Hong Kong dollars, accounting for about 3.84% of the total shares issued by the company as of this announcement date. The shares purchased will be used as incentives for eligible participants under the plan to encourage them to contribute to the group. As of this announcement date, the company has not granted any shares under this plan.